2016-003592-21: Evaluating the benefits of using secukinumab rather than standard treatments as the first systemic treatment in moderate to severe psoriasis |
|
|
| Ongoing | 4 | 148 | Europe | Secukinumab, Methotrexate 2.5mg tablets, Methotrexate 10 mg tablets, CICLOSPORIN 10mg capsule, CICLOSPORIN 25mg capsule, CICLOSPORIN 50mg capsule, CICLOSPORIN 100mg capsule, AIN457, Solution for injection in pre-filled syringe, Tablet, Capsule, COSENTYX | Novartis Pharmaceuticals UK Limited, Novartis Pharmaceuticals UK Limited | Moderate to severe plaque psoriasis, Moderate to severe plaque psoriasis. Psoriasis looks like red, raised scaly areas of skin., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
FORWARD OL, NCT04762498: A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout |
|
|
| Completed | 4 | 50 | US | Pegloticase, Methotrexate (MTX) | Amgen | Uncontrolled Gout, Chronic Gout | 05/23 | 12/23 | | |
| Active, not recruiting | 4 | 672 | Europe, Canada, US, RoW | Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C | Alimentiv Inc., Takeda Development Center Americas, Inc. | Colitis, Ulcerative | 03/26 | 03/26 | | |
